Virbac (VRBCF) Stock Price, News & Analysis

Company Overview

Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.

Key Stats

• Today's Range: $383.25 to $383.25
• 50-Day Range: $383.25 to $408.00
• 52-Week Range: $382.75 to $413.75
• Volume: N/A
• Average Volume: 100 shs
• Market Capitalization: N/A
• P/E Ratio: 57.95
• Dividend Yield: 0.50%
• Price Target: N/A
• Consensus Rating: N/A

Virbac Stock Analysis - MarketRank™

Virbac scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Virbac.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Virbac is 57.95, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.19.

Price to Earnings Ratio vs. Sector

The P/E ratio of Virbac is 57.95, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.28.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Virbac has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Virbac has recently increased by 16.68%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Virbac pays a meaningful dividend of 1.15%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Virbac does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Virbac is 28.73%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Virbac has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Healthcare companies.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Virbac insiders have not sold or bought any company stock.

Percentage Held by Institutions

24.31% of the stock of Virbac is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:VRBCF
• Previous Symbol: OTC:VRBCF
• CIK: 2029969
• Web: www.virbac.fr
• Phone: 33.4.92.08.71.00
• Fax: N/A
• Employees: 5,459
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 57.95
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A